Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Institutional response to FDA warning on aprotinin and impact on outcomes.
2
Zitationen
8
Autoren
2009
Jahr
Abstract
In response to new data and regulatory guidelines, we formulated guidelines based on expert review of data. We reduced aprotinin use, but more importantly, introduced an evidence-based approach to the use of aprotinin, consistent with regulatory guidelines. This model of guideline implementation can be useful in similar scenarios.
Ähnliche Arbeiten
A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care
1999 · 5.201 Zit.
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial
2010 · 3.231 Zit.
Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio and Mortality in Patients With Severe Trauma
2015 · 2.432 Zit.
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
2020 · 2.420 Zit.
A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care
1999 · 2.045 Zit.